Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 9/20 | 0.45 |
| ▸ | CA2 | P00918 | 9/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | GRK6 | P43250 | 2/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8711595 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL788634 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL375915 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL7030562 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL11289015 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL7198908 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL4278638 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL319584 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL4704343 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL7528649 | 0.99 | TSHR (0.48) | TSHRCA1CA2GSK3BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4621 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111589-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG RESISTANCE IN CELLS | MEDICI THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2024040220-A9 | CD83 BINDING FUSION PROTEINS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2025-02-27 | — | — | WO | claimed |
| US-20250009778-A1 | KRAS ANTAGONISTS | TRUETIVA INC (US) | 2025-01-09 | — | — | US | claimed |
| US-20240358708-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING LYMPHOID MALIGNANCY | Diacovo, Thomas (US) | 2024-10-31 | — | — | US | claimed |
| US-12116400-B2 | Albumin variants and conjugates | SARTORIUS ALBUMEDIX LIMITED (GB) | 2024-10-15 | — | — | US | claimed |
| US-20240199738-A1 | MONOCLONAL ANTIBODIES AND CONJUGATES AGAINST PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF | A & G PHARMACEUTICAL INC (US) | 2024-06-20 | — | — | US | claimed |
| WO-2024118760-A1 | PEPTIDE-LINKED DRUG DELIVERY SYSTEM | CORNELL UNIVERSITY (US) | 2024-06-06 | — | — | WO | claimed |
| US-11969428-B2 | Methods and pharmaceutical compositions for treating lymphoid malignancy | Diacovo, Thomas (US) | 2024-04-30 | — | — | US | claimed |
| EP-3243835-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-04-10 | — | — | EP | claimed |
| US-11952353-B2 | STAT3 transcription factor inhibitors and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2024-04-09 | — | — | US | claimed |
| EP-0531452-A1 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | NeXstar Pharmaceuticals, Inc. (US) | 1993-03-17 | — | — | EP | claimed |
| WO-1991018914-A1 | SYNTHESIS OF GLYCEROL DI- AND TRIPHOSPHATE DERIVATIVES | VICAL, INC. (US) | 1991-12-12 | — | — | WO | claimed |
| EP-0190050-B1 | METHOD FOR PREPARING SMALL VESICLES USING MICROEMULSIFICATION | VESTAR, INC. (US) | 1991-05-15 | — | — | EP | claimed |
| EP-0409227-A2 | Pyrimidine nucleosides, their preparation and pharmaceutical preparations | MATTHES, Eckart, Dr. (DE) | 1991-01-23 | — | — | EP | claimed |
| US-4753788-A | HOMOGENIZING LIPIDS | VESTAR RESEARCH INC. (US) | 1988-06-28 | — | — | US | claimed |
| EP-0190050-A2 | Method for preparing small vesicles using microemulsification | VESTAR, INC. (US) | 1986-08-06 | — | — | EP | claimed |
| US-4385112-A | CULTURES, PSEUDOMONAS, QUANTITATIVE NUCLEOSIDE ASSAY, MAKING NUCLEOSIDE-5-CARBOXYLIC ACIDS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1983-05-24 | — | — | US | claimed |
| EP-0034424-A2 | Seven-membered ring compounds as inhibitors of cytidine deaminase | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1981-08-26 | — | — | EP | claimed |
| WO-1981002164-A1 | SEVEN-MEMBERED RING COMPOUNDS AS INHIBITORS OF CYTIDINE DEAMINASE | US COMMERCE (US) | 1981-08-06 | — | — | WO | claimed |
| US-4275057-A | CANCER AND ANTITUMOR DRUG RESEARCH | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1981-06-23 | — | — | US | claimed |